

Table 3.6
Verified Primary and Other Cancers (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: March 31, 2018; Events through March 31, 2018

	MRC Super Cohort ¹	SRC Super Cohort ²
Number of participants	44174	117634
Mean follow-up (months)	173.0	188.2
Overall cancer	7772 (1.22%)	25348 (1.37%)
Primary cancer		
Breast cancer	2867 (0.45%)	10211 (0.55%)
Invasive breast cancer	2349 (0.37%)	8516 (0.46%)
Non-invasive breast cancer	572 (0.09%)	1833 (0.10%)
Ovarian cancer	266 (0.04%)	971 (0.05%)
Endometrial cancer ³	320 (0.09%)	1461 (0.13%)
Colorectal cancer	909 (0.14%)	2308 (0.13%)
Other cancer		
Accessory sinus	2 (<0.01%)	11 (<0.01%)
Adrenal gland	4 (<0.01%)	12 (<0.01%)
Anus	28 (<0.01%)	91 (<0.01%)
Appendix	12 (<0.01%)	30 (<0.01%)
Base of tongue	8 (<0.01%)	24 (<0.01%)
Biliary tract, parts of (other/unspecified)	57 (0.01%)	137 (0.01%)
Bladder	238 (0.04%)	748 (0.04%)
Bones/joints/articular cartilage (limbs)	2 (<0.01%)	11 (<0.01%)
Bones/joints/articular cartilage (other)	8 (<0.01%)	18 (<0.01%)
Brain	67 (0.01%)	292 (0.02%)
Cervix	41 (0.01%)	84 (<0.01%)
Central Nervous System (excludes brain)	1 (<0.01%)	3 (<0.01%)
Connective/subcutaneous/soft tissues	42 (0.01%)	137 (0.01%)
Endocrine glands, related structures	0 (0.00%)	4 (<0.01%)
Esophagus	47 (0.01%)	126 (0.01%)
Eye and adnexa	24 (<0.01%)	59 (<0.01%)
Gallbladder	33 (0.01%)	73 (<0.01%)
Genital organs	71 (0.01%)	255 (0.01%)
Gum	5 (<0.01%)	37 (<0.01%)
Heart	4 (<0.01%)	30 (<0.01%)
Kidney	191 (0.03%)	529 (0.03%)
Larynx	21 (<0.01%)	32 (<0.01%)
Leukemia	244 (0.04%)	827 (0.04%)
Liver	90 (0.01%)	207 (0.01%)
Lung	1081 (0.17%)	2855 (0.15%)
Lymph nodes	1 (<0.01%)	2 (<0.01%)
Lymphoma, Hodgkins	22 (<0.01%)	52 (<0.01%)
Lymphoma, non-Hodgkins	366 (0.06%)	1372 (0.07%)
Melanoma of the skin	359 (0.06%)	2071 (0.11%)
Multiple myeloma	193 (0.03%)	414 (0.02%)
Mycosis fungoides	7 (<0.01%)	19 (<0.01%)
Oral (mouth)	6 (<0.01%)	30 (<0.01%)
Palate	7 (<0.01%)	25 (<0.01%)
Pancreas	312 (0.05%)	876 (0.05%)
Parotid gland (Stensen's duct)	13 (<0.01%)	45 (<0.01%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Black/African American and Hispanic/Latina participants from the CT and OS.

² The SRC Super Cohort includes all White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

³ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.

Table 3.6 (continued)
Verified Primary and Other Cancers (Annualized Percentages): MRC and SRC Super Cohort Participants

Data as of: March 31, 2018; Events through March 31, 2018

	MRC Super Cohort¹	SRC Super Cohort²
Number of participants	44174	117634
Mean follow-up (months)	173.0	188.2
Peripheral nerves and autonomic nervous system	0 (0.00%)	2 (<0.01%)
Peritoneum	43 (0.01%)	138 (0.01%)
Pyriiform sinus	0 (0.00%)	2 (<0.01%)
Renal pelvis	30 (<0.01%)	87 (<0.01%)
Respiratory system, intrathoracic, other	0 (0.00%)	3 (<0.01%)
Salivary glands, major (other/unspecified)	3 (<0.01%)	15 (<0.01%)
Stomach	95 (0.01%)	197 (0.01%)
Thyroid	101 (0.02%)	389 (0.02%)
Tongue, part of (other/unspecified)	15 (<0.01%)	68 (<0.01%)
Ureter	14 (<0.01%)	59 (<0.01%)
Urinary organs (other/unspecified)	9 (<0.01%)	25 (<0.01%)
Uterus, not otherwise specified ³	28 (0.01%)	86 (0.01%)
Other/unknown site of cancer	199 (0.03%)	594 (0.03%)
Other/unknown cancers reported on death form	104 (0.02%)	378 (0.02%)

¹ The MRC Super Cohort includes all WHI Hormone Trial participants and all Black/African American and Hispanic/Latina participants from the CT and OS.

² The SRC Super Cohort includes all White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

³ Only women without a baseline hysterectomy are used to compute the annual rates of endometrial and uterine cancer.